{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 912311f3-4e01-4f73-9269-bffd7030dd74 --><h2>Azithromycin</h2><!-- end field 912311f3-4e01-4f73-9269-bffd7030dd74 -->","summary":"","htmlStringContent":"<!-- begin item dc979cbd-a97f-49c4-b0eb-abc3aedc5344 --><!-- end item dc979cbd-a97f-49c4-b0eb-abc3aedc5344 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"73f45a07-bddc-54ea-a84f-a243d163adbf","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3b0e73e3-4bac-458d-905f-49e56b5602bb --><h3>What contraindications and cautions are important with azithromycin?</h3><!-- end field 3b0e73e3-4bac-458d-905f-49e56b5602bb -->","summary":"","htmlStringContent":"<!-- begin item c1de8660-5e8c-4d94-bbc5-cfc735f86b72 --><!-- begin field 84fc094a-67d9-4c36-b83d-123ec10c4d2a --><p><strong> Do not prescribe azithromycin to people:</strong></p><ul><li>With severe hepatic impairment.</li><li>Taking drugs that prolong the QT interval (for example amiodarone, sotalol, terfenadine, and amisulpride) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With hypokalaemia, due to the risk of prolongation of the QT interval.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li></ul><p><strong>Prescribe azithromycin with caution to people with:</strong></p><ul><li>Mild to moderate hepatic impairment.</li><li>Moderate to severe renal impairment.</li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 84fc094a-67d9-4c36-b83d-123ec10c4d2a --><!-- end item c1de8660-5e8c-4d94-bbc5-cfc735f86b72 -->","subChapters":[]},{"id":"aace6f32-e417-558b-bcef-b884d31745a4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 58e5a22a-8103-4ddc-abd6-4bd4405ff396 --><h3>What are the adverse effects of azithromycin?</h3><!-- end field 58e5a22a-8103-4ddc-abd6-4bd4405ff396 -->","summary":"","htmlStringContent":"<!-- begin item 57b74133-dbbf-40c2-ac92-d3caf13f18cd --><!-- begin field 0ed9e9cb-1ebd-4d10-a886-9ef2ba3027a1 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides.</li><li><strong>Consider pseudomembranous colitis</strong> if a person develops severe diarrhoea during or after treatment with azithromycin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with azithromycin.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> have been reported following treatment with azithromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> drug reaction with eosinophilia and systemic symptoms (DRESS), pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 0ed9e9cb-1ebd-4d10-a886-9ef2ba3027a1 --><!-- end item 57b74133-dbbf-40c2-ac92-d3caf13f18cd -->","subChapters":[]},{"id":"fdd48dfe-4dcd-5e5b-bad0-f6985d2193b5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e990197e-f63b-4df6-942e-a9e57cf0d045 --><h3>What drug interactions are important with azithromycin?</h3><!-- end field e990197e-f63b-4df6-942e-a9e57cf0d045 -->","summary":"","htmlStringContent":"<!-- begin item fafa287b-3884-401e-bbcf-d19c128552b6 --><!-- begin field 7c1e427a-ebc1-4039-b6aa-e77f48430793 --><ul><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— the manufacturer reports post-marketing cases of rhabdomyolysis in people taking azithromycin with statins, although this appears to be less common than with other macrolides.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Ciclosporin </strong>— azithromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-<sub>2</sub> agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li><li><strong>Colchicine </strong>— concomitant administration has been reported to increase levels of P-glycoprotein substrate. This protein has been linked to barriers to successful chemotherapy treatment in cancer.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 7c1e427a-ebc1-4039-b6aa-e77f48430793 --><!-- end item fafa287b-3884-401e-bbcf-d19c128552b6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}